[go: up one dir, main page]

BRPI0407058A - Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento - Google Patents

Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento

Info

Publication number
BRPI0407058A
BRPI0407058A BR0407058-5A BRPI0407058A BRPI0407058A BR PI0407058 A BRPI0407058 A BR PI0407058A BR PI0407058 A BRPI0407058 A BR PI0407058A BR PI0407058 A BRPI0407058 A BR PI0407058A
Authority
BR
Brazil
Prior art keywords
beta
disease
methods
treatment
prophylaxis
Prior art date
Application number
BR0407058-5A
Other languages
English (en)
Inventor
Frederique Bard
Nicki Vasquez
Peter A Seubert
Ted Yednock
Original Assignee
Neuralab Ltd
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32850829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0407058(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuralab Ltd, Wyeth Corp filed Critical Neuralab Ltd
Publication of BRPI0407058A publication Critical patent/BRPI0407058A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODOS DE PROFILAXIA E DE TRATAMENTO DE UMA DOENçA, COMPOSIçãO FARMACêUTICA, E, USO DE UM FRAGMENTO". A invenção provê métodos úteis para realizar profilaxia ou tratamento da Doença de Alzheimer. Tais métodos requerem a administração de fragmentos A-beta de regiões centrais ou terminais-C de A-beta. Tais fragmentos podem induzir uma mistura policlonal de anticorpos que especificamente ligam-se a A-beta solúvel, sem ligarem-se a placas. Os anticorpos podem inibir a formação de depósitos aminóides de A-beta no cérebro de um paciente de A<225>, assim evitando ou tratando a doença. O fragmento A-beta 15-24 e seus subfragmentos de 5-10 aminoácidos contíguos são imunógenos preferidos, devido a sua capacidade de gerar um elevado título de anticorpos.
BR0407058-5A 2003-02-01 2004-01-31 Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento BRPI0407058A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44415003P 2003-02-01 2003-02-01
PCT/US2004/002856 WO2004069182A2 (en) 2003-02-01 2004-01-31 Active immunization to generate antibodies to soluble a-beta

Publications (1)

Publication Number Publication Date
BRPI0407058A true BRPI0407058A (pt) 2006-01-17

Family

ID=32850829

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407058-5A BRPI0407058A (pt) 2003-02-01 2004-01-31 Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento

Country Status (20)

Country Link
US (3) US20060188512A1 (pt)
EP (1) EP1594969B1 (pt)
JP (1) JP2006516639A (pt)
KR (1) KR20050118669A (pt)
CN (1) CN1745175A (pt)
AU (1) AU2004209981B2 (pt)
BR (1) BRPI0407058A (pt)
CA (1) CA2513722A1 (pt)
CR (1) CR7922A (pt)
EC (1) ECSP055939A (pt)
ES (1) ES2545765T3 (pt)
HR (1) HRP20050670A2 (pt)
MX (1) MXPA05008156A (pt)
NO (1) NO20053862L (pt)
NZ (1) NZ567324A (pt)
PL (1) PL378571A1 (pt)
RU (1) RU2390350C2 (pt)
UA (1) UA87453C2 (pt)
WO (1) WO2004069182A2 (pt)
ZA (1) ZA200505782B (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP2006516639A (ja) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
ES2246177B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
TWI374893B (en) * 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
JP2005181711A (ja) 2003-12-19 2005-07-07 Ricoh Co Ltd 画像形成装置及びプロセスカートリッジ
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
CA2582157A1 (en) * 2004-10-05 2006-04-20 Wyeth Methods and compositions for improving recombinant protein production
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CA2607868A1 (en) * 2005-05-05 2006-11-16 Merck & Co., Inc. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
JPWO2006126682A1 (ja) * 2005-05-27 2008-12-25 財団法人化学及血清療法研究所 アルツハイマー病の予防・治療用ワクチン
EP1896506B1 (en) * 2005-06-17 2013-01-02 Janssen Alzheimer Immunotherapy Methods of purifying anti a beta antibodies
US9133267B2 (en) * 2005-11-22 2015-09-15 The Trustees Of The University Of Pennsylvania Antibody treatment of Alzheimer's and related diseases
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
SI2361638T1 (sl) 2005-12-12 2014-05-30 Ac Immune S.A. A-beta 1-42 specifiäśna, monoklonska protitelesa s terapevtskimi lastnostmi
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN101058608B (zh) * 2006-04-21 2011-02-23 杜如昱 人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途
JP2009538924A (ja) 2006-06-01 2009-11-12 エラン ファーマシューティカルズ，インコーポレイテッド Ａｐｐの神経活性断片
EP2468770B1 (en) 2006-07-14 2017-12-20 AC Immune S.A. Humanized antibody against amyloid beta.
EP2061507A4 (en) * 2006-08-14 2010-08-18 Thymon Llc COMPOSITIONS AND METHODS FOR THE TREATMENT AND PROPHYLAXIS OF SEVERAL HIV-1 STRAINS AND SUB-TYPES
US20090123488A1 (en) * 2006-08-14 2009-05-14 Thymon, Llc Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8077343B1 (en) 2007-01-03 2011-12-13 Marvell International Ltd. Determining end of print job in handheld image translation device
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CN101842107B (zh) * 2007-07-26 2014-04-23 雷文斯治疗公司 抗微生物肽，组合物和使用方法
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
EP2197914A1 (en) * 2007-09-13 2010-06-23 Delenex Therapeutics AG HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE
PL2238166T3 (pl) 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
DK2475428T3 (en) 2009-09-11 2015-09-28 Probiodrug Ag Heterocyclic derivatives as glutaminylcyklaseinhibitorer
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
BR112012022478B1 (pt) 2010-03-10 2021-09-21 Probiodrug Ag Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
NZ606357A (en) 2010-07-30 2015-05-29 Genentech Inc Safe and functional humanized anti beta-amyloid antibody
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
AU2011322553B2 (en) 2010-10-26 2015-07-02 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
KR20160099732A (ko) * 2011-09-23 2016-08-22 에이씨 이뮨 에스.에이. 백신 요법
KR101755065B1 (ko) * 2013-07-03 2017-07-06 경희대학교 산학협력단 에클랄바사포닌 또는 그 유도체를 포함하는 인지기능 장애 또는 집중력 장애 질환 예방 또는 치료용 약학 조성물
DE102016005169B3 (de) * 2016-04-29 2017-07-13 Forschungszentrum Jülich GmbH Verfahren zur Identifikation von Inhibitoren der primären Nukleation der Amyloid-Beta-Aggregation
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
CA3099946A1 (en) * 2018-05-18 2019-11-21 Universite Laval Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3787140A (en) * 1971-10-04 1974-01-22 A Gregory Power plant
US6096318A (en) * 1973-05-07 2000-08-01 The Ohio State University Antigenically modified HCG polypeptides
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5158769A (en) * 1984-03-07 1992-10-27 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US5417986A (en) * 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5208036A (en) * 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5096706A (en) * 1986-03-25 1992-03-17 National Research Development Corporation Antigen-based treatment for adiposity
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5278049A (en) * 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5220013A (en) * 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US5187153A (en) * 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US4912206A (en) * 1987-02-26 1990-03-27 The United States Of America As Represented By The Department Of Health And Human Services CDNA clone encoding brain amyloid of alzheimer's disease
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5004697A (en) * 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5231000A (en) * 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US5089603A (en) * 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
WO1991018980A1 (en) 1990-06-01 1991-12-12 Cetus Corporation Compositions and methods for identifying biologically active molecules
DE69133372T2 (de) * 1990-06-15 2005-02-24 Scios Inc., Sunnyvale Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
DK0971033T3 (da) 1991-01-21 2009-12-14 Elan Pharm Inc Test og model til Alzheimers sygdom
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
JP2001524926A (ja) 1991-09-18 2001-12-04 アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ オリゴマーの雑多ライブラリーの集合体を合成する方法
NZ249704A (en) * 1992-02-11 1996-11-26 Jackson H M Found Military Med A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5851787A (en) * 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
US5736141A (en) 1992-06-05 1998-04-07 Dalhousie University Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and Freund's adjuvant
WO1993025210A1 (en) * 1992-06-18 1993-12-23 President And Fellows Of Harvard College Diphtheria toxin vaccines
US5837672A (en) * 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US6610493B1 (en) * 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5736142A (en) * 1993-09-14 1998-04-07 Cytel Corporation Alteration of immune response using pan DR-binding peptides
CN1091138A (zh) * 1992-08-27 1994-08-24 迪金研究有限公司 疫苗
US5958883A (en) * 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
DK0665897T3 (da) 1992-10-01 2003-10-20 Univ Columbia Komplekse, kombinatoriske, kemiske biblioteker kodet med etiketter
US5605811A (en) * 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
WO1994017197A1 (en) * 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTIBODY AGAINST β-AMYLOID OR DERIVATIVE THEREOF AND USE THEREOF
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
DE614989T1 (de) * 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
ATE386800T1 (de) * 1993-03-17 2008-03-15 Us Gov Health & Human Serv Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
FI955667L (fi) * 1993-05-25 1996-01-12 American Cyanamid Co Adjuvantteja RS-viruksen vastaisia rokotteita varten
US5652334A (en) * 1993-09-08 1997-07-29 City Of Hope Method for design of substances that enhance memory and improve the quality of life
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5858981A (en) * 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
JPH09508353A (ja) 1993-11-02 1997-08-26 アフィマックス テクノロジーズ ナムローゼ フェンノートシャップ 分子多様性の合成及びスクリーニング
US5744368A (en) * 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
CA2182311A1 (en) * 1994-01-27 1995-08-03 Karen Hsiao Transgenic non-human mammals with progressive neurologic disease
US6270757B1 (en) * 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
CA2189634A1 (en) 1994-05-06 1995-11-16 John J. Baldwin Combinatorial dihydrobenzopyran library
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
WO1996024369A1 (en) * 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US5624937A (en) * 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) * 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5910427A (en) * 1995-06-22 1999-06-08 La Jolla Institute For Allergy And Immunology Antigen non-specific glycosylation inhibiting factor derivatives
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6015662A (en) * 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6057367A (en) * 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US6022859A (en) * 1996-11-15 2000-02-08 Wisconsin Alumni Research Foundation Inhibitors of β-amyloid toxicity
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5798102A (en) * 1997-03-04 1998-08-25 Milkhaus Laboratory, Inc. Treatment of cardiomyopathy
US6057098A (en) * 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
CZ9903657A3 (cs) * 1997-04-15 2001-09-12 Farmaceutisk Laboratorium Ferring A/S Modifikované molekuly TNFalfa, DNA kódující takové modifikované molekuly TNFalfa a vakcíny obsahující uvedené modifikované molekuly TNFalfa
US6787319B2 (en) * 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
ATE370740T1 (de) * 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
US6175057B1 (en) * 1997-10-08 2001-01-16 The Regents Of The University Of California Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
US6710226B1 (en) * 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) * 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20050059591A1 (en) * 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
DE69920897T2 (de) * 1998-04-28 2005-10-13 Smithkline Beecham Corp. Monoklonale antikörper mit verringerter immunisierungsfähigkeit
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6432710B1 (en) * 1998-05-22 2002-08-13 Isolagen Technologies, Inc. Compositions for regenerating tissue that has deteriorated, and methods for using such compositions
US6727349B1 (en) * 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
US7112661B1 (en) * 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
US7629311B2 (en) * 1999-02-24 2009-12-08 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
US7282570B2 (en) * 1999-04-20 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DK1409654T3 (da) * 1999-06-16 2008-12-08 Boston Biomedical Res Inst Immunologisk styring af beta-amyloid-niveauer in vivo
DE60044057D1 (de) * 1999-09-03 2010-05-06 Univ Ramot Verbindungen, zusammensetzungen und verfahren zur behandlung oder vorsorge von alzheimer erkrankung
JP2001076325A (ja) * 1999-09-07 2001-03-23 Canon Inc 変位検出装置及び情報記録装置
US6824780B1 (en) * 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
PT1257584E (pt) * 2000-02-24 2005-01-31 Lilly Co Eli Anticorpos humanizados que sequestram peptido beta-amiloide
JP5362164B2 (ja) * 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
WO2002064084A2 (en) * 2000-11-02 2002-08-22 Cornell Research Foundation, Inc. In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
DE10064895A1 (de) * 2000-12-23 2002-06-27 Alstom Switzerland Ltd Kühlsystem und Verfahren zur Kühlung eines Strömungsmaschinengehäuses
AU2002258808A1 (en) * 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
US20030135035A1 (en) * 2001-08-09 2003-07-17 Mark Shannon Human ZZAP1 protein
US7781413B2 (en) * 2001-10-31 2010-08-24 Board Of Regents, The University Of Texas System SEMA3B inhibits tumor growth and induces apoptosis in cancer cells
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2003265509A (ja) * 2002-03-18 2003-09-24 Masaharu Takenaga 脱腸帯
TWI221474B (en) * 2002-10-23 2004-10-01 Chung Shan Inst Of Science Method for preparing melamine salt of bis-(pentaerythritol phosphate) phosphoric acid
JP2006516639A (ja) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
TWI374893B (en) * 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20060182321A1 (en) * 2003-07-07 2006-08-17 Agency For Science, Technology And Research Method and apparatus for extracting third ventricle information
CA2445743A1 (en) * 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
WO2005058940A2 (en) * 2003-12-17 2005-06-30 Wyeth Immunogenic peptide carrier conjugates and methods of producing same
CA2549552A1 (en) * 2003-12-17 2005-06-30 Elan Pharmaceuticals, Inc. A.beta. immunogenic peptide carrier conjugates and methods of producing same
US20050214222A1 (en) * 2004-02-13 2005-09-29 Mckinnon Stuart J In vivo imaging of amyloid plaques in glaucoma using intravenous injectable dyes
PL1771208T3 (pl) * 2004-07-02 2013-11-29 Univ Pittsburgh Commonwealth Sys Higher Education Zastosowanie radioznakowanych pochodnych tioflawiny w obrazowaniu amyloidu dla oceny terapii antyamyloidowej
KR20070040824A (ko) * 2004-07-30 2007-04-17 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법
CA2582157A1 (en) * 2004-10-05 2006-04-20 Wyeth Methods and compositions for improving recombinant protein production
US20060160161A1 (en) * 2004-10-26 2006-07-20 Elan Pharmaceuticals, Inc. Methods for assessing antibodies to neurodegenerative disease-associated antigens
CA2589017A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
WO2006066118A2 (en) * 2004-12-15 2006-06-22 Neuralab Limited Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment
TW200636066A (en) * 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
CA2590337C (en) * 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
WO2006066233A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
AR052469A1 (es) * 2005-01-28 2007-03-21 Wyeth Corp Formulaciones liquidas estabilizadas de polipeptido
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP1896506B1 (en) * 2005-06-17 2013-01-02 Janssen Alzheimer Immunotherapy Methods of purifying anti a beta antibodies
ATE550338T1 (de) * 2005-07-18 2012-04-15 Merck Sharp & Dohme Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
WO2007059000A2 (en) * 2005-11-10 2007-05-24 Roskamp Research, Llc Modulation of angiogenesis by a-beta peptide fragments
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN101970000A (zh) * 2007-04-18 2011-02-09 杨森阿尔茨海默氏症免疫治疗公司 脑淀粉样血管病的预防和治疗
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl) * 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP5730020B2 (ja) * 2007-12-28 2015-06-03 ネオトープ バイオサイエンシーズ リミテッド アミロイドーシスの処置および予防

Also Published As

Publication number Publication date
ES2545765T3 (es) 2015-09-15
EP1594969B1 (en) 2015-05-20
EP1594969A4 (en) 2006-07-26
US20080279873A1 (en) 2008-11-13
EP1594969A2 (en) 2005-11-16
NZ567324A (en) 2009-08-28
CA2513722A1 (en) 2004-08-19
PL378571A1 (pl) 2006-05-02
RU2005127429A (ru) 2006-02-10
AU2004209981B2 (en) 2009-02-26
JP2006516639A (ja) 2006-07-06
ECSP055939A (es) 2006-04-19
KR20050118669A (ko) 2005-12-19
RU2390350C2 (ru) 2010-05-27
NO20053862D0 (no) 2005-08-18
UA87453C2 (ru) 2009-07-27
WO2004069182A3 (en) 2005-03-03
US20040213800A1 (en) 2004-10-28
MXPA05008156A (es) 2005-09-30
US20060188512A1 (en) 2006-08-24
ZA200505782B (en) 2006-09-27
HRP20050670A2 (en) 2005-12-31
AU2004209981A1 (en) 2004-08-19
CN1745175A (zh) 2006-03-08
CR7922A (es) 2006-02-07
WO2004069182A2 (en) 2004-08-19
NO20053862L (no) 2005-10-31

Similar Documents

Publication Publication Date Title
BRPI0407058A (pt) Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento
EP2400021A3 (en) ErbB3 based methods and compositions for treating neoplasms
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
ATE330967T1 (de) An her2 bindende peptidverbindungen
CY1119376T1 (el) Αντισωματα ειδικα για τη μορφη πρωτοϊνιδιου της βητα-αμυλοειδους πρωτεϊνης
PT942740E (pt) Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf
NO961326L (no) Inhibitorer av -amyloidproteinproduksjon
BRPI0418351A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
NO20083793L (no) Antistoffer mot amyloid-beta peptid
BRPI0410129B8 (pt) anticorpo anti-cs1 isolado, fragmento de ligação de antígeno, composto conjugado e composição farmacêutica
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
BRPI0513798A (pt) anticorpos anti-cd154
BRPI0408317A (pt) anticorpos do receptor de igf-i para o tratamento de cáncer
BR9911389A (pt) Composição de peptìdio como imunógeno para o tratamento de alergia
WO2005000244A3 (en) Methods and compositions for treating rheumatoid arthritis
BR0011000A (pt) Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico
BR112021021224A2 (pt) Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo
NZ607886A (en) Nogo receptor binding protein
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
ATE402958T1 (de) Antagonisten des ige-rezeptors
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
BRPI0416777A (pt) composto de piridinil metanona substituìdos por amino úteis no tratamento de disturbios da quinase
BR9910589A (pt) Anticorpo humanizado, processo para produzir anticorpo humanizado vtm1-1, composição farmacêutica, e, processo para tratar um paciente sofrendo ou em risco dos efeitos tóxicos de uma verotoxina, e, linhagem de célula
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
WO2005079541A3 (en) Terephthalamide peptidomimetic compounds and methods

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: WYETH (US) , ELAN PHARMA INTERNATIONAL LIMITED (IE

Free format text: TRANSFERIDO DE: NEURALAB LIMITED

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: WYETH (US) , ELAN PHARMA INTERNATIONAL LIMITED (IE

B25A Requested transfer of rights approved

Owner name: WYETH (US) , CRIMAGUA LIMITED (IE)

B25A Requested transfer of rights approved

Owner name: WYETH (US) , JANSSEN ALZHEIMER IMMUNOTHERAPY (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN ALZHEIMER IMMUNOTHERAPY (IE) , WYETH LLC (

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2499 DE 27-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.